Drug class

LHrH(GNrH) Agonist Analog Pituitary Suppressants

Luteinizing hormone-releasing hormone (gonadotropin-releasing hormone) agonist analog pituitary suppressants are synthetic peptide derivatives that modulate the hypothalamic-pituitary-gonadal axis. Read more about LHrH(GNrH) Agonist Analog Pituitary Suppressants

38 drugs in this class 18 manufacturers

Advertisement

Drugs in LHrH(GNrH) Agonist Analog Pituitary Suppressants

Showing 28–36 of 38 drugs

LEUPROLIDE ACETATE

LHRH(GNRH) AGONIST ANALOG PITUITARY SUPPRESSANTS · ADVANCED PROSTATIC CARCINOMA ·+1
PHARMACEU ASSOC

LEUPROLIDE ACETATE

LHRH(GNRH) AGONIST ANALOG PITUITARY SUPPRESSANTS · ADVANCED PROSTATIC CARCINOMA ·+1
EUGIA US LLC

LEUPROLIDE ACETATE

LHRH(GNRH) AGONIST ANALOG PITUITARY SUPPRESSANTS · ADVANCED PROSTATIC CARCINOMA ·+1
MEITHEAL PHARMA

LEUPROLIDE ACETATE

LHRH(GNRH) AGONIST ANALOG PITUITARY SUPPRESSANTS · ADVANCED PROSTATIC CARCINOMA ·+1
VGYAAN PHARMACE
Filter & compare in the drug finder → Opens the drug finder with LHrH(GNrH) Agonist Analog Pituitary Suppressants preselected. Add indication or manufacturer filters there.

About LHrH(GNrH) Agonist Analog Pituitary Suppressants.

Luteinizing hormone-releasing hormone (gonadotropin-releasing hormone) agonist analog pituitary suppressants are synthetic peptide derivatives that modulate the hypothalamic-pituitary-gonadal axis.

Although an initial administration induces a transient surge in gonadotropin release, chronic and continuous exposure paradoxically downregulates and desensitizes pituitary receptors, profoundly suppressing luteinizing hormone and follicle-stimulating hormone secretion.

This reversible inhibition depresses circulating sex hormones to castrate or postmenopausal levels, halting hormone-driven cellular proliferation.

Consequently, these agents serve as pivotal therapies in hormone-dependent oncology settings such as advanced prostate cancer and premenopausal breast cancer, as well as in benign sex-steroid-dependent disorders including endometriosis, uterine leiomyomas, and central precocious puberty.